why are people selling?, page-9

Hi Juzzy

By my reckoning, updates are overdue on the:

- AIM Program;
- Anti body program (HU91);
- MK Elisa, vis-a-vis where the CE mark is taking it;
- Japanese mass screening trials; and
- Canine trials.

I don't expect additional formal notification from Quest Diagnistics unlil the end oth the year BUT they will be presenting at conferences and pointing to near term development (including biomarkers) prior to then.

From left field there is always the possibility of new licences and patent approvals.

And current thinking on the efficacy/necessity of midkine as a biomarker and midkine antibodies as a therapeutic. Perhaps the broader issues could be discussed following the conference. Input from an market analyst (with an eye for science) would also be great.

cheers